Home » Novartis' Diovan Gets EU Nod for Treatment of Heart Attack Survivors
Novartis' Diovan Gets EU Nod for Treatment of Heart Attack Survivors
Novartis AG has successfully
completed the EU Mutual Recognition Procedure (MRP) in 14 countries for Diovan
(valsartan) for the treatment of heart attack survivors. According to the company
release, Diovan, a proven, powerful antihypertensive agent, is now indicated
as a potentially life-saving therapy for the more than 7.50 lakh people in the
EU who are at risk of a recurrent heart attack or other serious outcomes such
as cardiovascular mortality, hospitalization for heart failure, resuscitated
cardiac arrest or stroke.
Pharmabiz
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
07May
-
14May
-
30May